Biomarker Discovery Outsourcing Services Market: Detailed Company Profiles

By /

Biomarker Discovery Outsourcing Services Market Companies

Biomarker Discovery Outsourcing Services Market Companies
  • Eurofins Scientific
  • Charles River Laboratories
  • ICON plc
  • Labcorp Drug Development
  • Thermo Fisher Scientific
  • WuXi AppTec
  • Syneos Health
  • Q² Solutions (IQVIA & Quest Diagnostics JV)
  • Bio-Rad Laboratories
  • PPD Inc. (Thermo Fisher Scientific)
  • SGS SA
  • Evotec SE
  • Creative Biolabs
  • GenScript Biotech Corporation
  • DiscoverX (Eurofins Discovery)
  • Proteome Sciences plc
  • Medpace Holdings, Inc.
  • Precision for Medicine
  • Sino Biological Inc.
  • Biomarker Technologies, Inc.

View Full Report

1. Eurofins Scientific

  • Company Name and Headquarters: Eurofins Scientific SE, Luxembourg City, Luxembourg

  • Product Offerings related to Biomarker Discovery Outsourcing Services: Eurofins provides a comprehensive suite of services including genomics, proteomics, metabolomics, bioinformatics, and a wide array of specialized biomarker assays. They offer services across the entire drug discovery and development pipeline, from target identification to clinical trials, focusing on high-throughput screening, compound profiling, and assay development.

  • Market Share and Estimated Revenue from Biomarker Discovery Outsourcing Services Segment: Eurofins holds a significant market share, particularly in the analytical testing and contract research services sector. While specific revenue for “biomarker discovery outsourcing” is not disaggregated, their overall Life Sciences segment generates substantial revenue, with biomarker-related services contributing a significant portion due to their extensive network of specialized labs.

  • Recent Developments, Partnerships, or Innovations: Eurofins consistently expands its service portfolio through acquisitions (e.g., DiscoverX, mentioned later). They are known for investing in advanced analytical technologies and have recently focused on expanding their genomics and bioinformatics capabilities to support precision medicine.

  • Competitive Positioning and Strategic Focus: Eurofins’ strength lies in its vast global network of accredited laboratories, offering a broad spectrum of specialized analytical and bioanalytical services. Their strategic focus is on providing integrated solutions, leveraging their diverse expertise to cater to complex R&D needs across pharmaceuticals, biotechnology, and diagnostics.

  • Key Customers or Industries Served: Pharmaceutical companies, biotechnology firms, academic and research institutions, CROs, and diagnostic companies.

2. Charles River Laboratories

  • Company Name and Headquarters: Charles River Laboratories International, Inc., Wilmington, Massachusetts, USA

  • Product Offerings related to Biomarker Discovery Outsourcing Services: Charles River offers a wide range of services spanning early-stage drug discovery, including target identification and validation, in vivo pharmacology, safety assessment, and a strong focus on biomarker discovery and validation using various platforms (genomics, proteomics, immunophenotyping). They also provide bioinformatics support.

  • Market Share and Estimated Revenue from Biomarker Discovery Outsourcing Services Segment: Charles River is a leading global early-stage CRO. While precise biomarker revenue is not disclosed, their Discovery and Safety Assessment segment is a major revenue driver, with biomarker services being integral to many of their preclinical and translational research programs.

  • Recent Developments, Partnerships, or Innovations: Recent activities include expanding their gene therapy and cell therapy capabilities, which often involve complex biomarker identification. They frequently engage in strategic acquisitions to bolster their scientific expertise and technological platforms.

  • Competitive Positioning and Strategic Focus: Charles River is a powerhouse in preclinical and early-stage drug development, known for its strong scientific expertise and integrated solutions. Their strategic focus is on partnering with clients from discovery through IND submission, offering comprehensive research models and outsourced services that accelerate drug development.

  • Key Customers or Industries Served: Pharmaceutical companies, biotechnology firms, government agencies, and academic institutions.

3. ICON plc

  • Company Name and Headquarters: ICON plc, Dublin, Ireland

  • Product Offerings related to Biomarker Discovery Outsourcing Services: As a full-service CRO, ICON offers comprehensive biomarker strategies and services throughout the clinical development lifecycle. This includes biomarker assay development and validation, sample logistics, central laboratory services (genomics, proteomics, flow cytometry, immunoassay), and biomarker data management and analysis.

  • Market Share and Estimated Revenue from Biomarker Discovery Outsourcing Services Segment: ICON is one of the largest global CROs. Biomarker services are a critical component of their central lab and clinical research offerings. The acquisition of PRA Health Sciences significantly expanded their capabilities in this area.

  • Recent Developments, Partnerships, or Innovations: The acquisition of PRA Health Sciences in 2021 was a landmark event, substantially increasing their scale and therapeutic expertise. They are continuously investing in digital solutions and advanced analytics for clinical trial optimization, including biomarker data integration.

  • Competitive Positioning and Strategic Focus: ICON’s strength lies in its global reach and full-service CRO capabilities, providing end-to-end clinical trial solutions. Their strategic focus is on integrating data, technology, and scientific expertise to accelerate clinical development, with biomarkers playing a crucial role in patient stratification and response monitoring.

  • Key Customers or Industries Served: Large pharmaceutical companies, emerging and mid-sized biotechnology firms, and medical device companies.

4. Labcorp Drug Development (formerly Covance Drug Development)

  • Company Name and Headquarters: Labcorp Drug Development (part of Laboratory Corporation of America Holdings), Burlington, North Carolina, USA

  • Product Offerings related to Biomarker Discovery Outsourcing Services: Labcorp offers extensive biomarker services, including early-stage discovery, assay development and validation, central laboratory testing (genomics, proteomics, metabolomics, flow cytometry, immunology), and specialized biomarker analysis for clinical trials. They leverage their vast clinical diagnostics and drug development expertise.

  • Market Share and Estimated Revenue from Biomarker Discovery Outsourcing Services Segment: Labcorp is a major player in both clinical diagnostics and drug development, making them a significant force in biomarker services. Their Drug Development segment’s revenue is substantial, with biomarker services being an integral part of their offerings.

  • Recent Developments, Partnerships, or Innovations: Labcorp consistently invests in new technologies and service expansions, particularly in precision medicine, companion diagnostics, and advanced genomic testing. They often partner with pharmaceutical companies to develop and validate novel biomarkers.

  • Competitive Positioning and Strategic Focus: Labcorp’s unique position stems from combining a leading clinical diagnostics business with a top-tier drug development CRO. Their strategic focus is on providing integrated solutions from discovery to commercialization, leveraging their extensive data and testing capabilities to accelerate therapies and improve patient care.

  • Key Customers or Industries Served: Pharmaceutical and biotechnology companies, academic institutions, and government agencies.

5. Thermo Fisher Scientific

  • Company Name and Headquarters: Thermo Fisher Scientific Inc., Waltham, Massachusetts, USA

  • Product Offerings related to Biomarker Discovery Outsourcing Services: While primarily a provider of scientific instrumentation, reagents, and software, Thermo Fisher also offers outsourced services through its PPD clinical research business (acquired in 2021) and various specialized divisions. These services include advanced mass spectrometry for proteomics and metabolomics, genomics services, and a wide array of analytical testing and CRO services related to biomarker discovery and validation.

  • Market Share and Estimated Revenue from Biomarker Discovery Outsourcing Services Segment: Thermo Fisher is a dominant force in the life sciences tools market. The acquisition of PPD significantly elevated their presence in the CRO space, making them a major player in outsourced biomarker services. Precise revenue for this specific segment is embedded within their broader analytical instruments and CRO divisions.

  • Recent Developments, Partnerships, or Innovations: Thermo Fisher is at the forefront of innovation in analytical instrumentation (e.g., mass spectrometers, next-generation sequencing platforms). Their strategic focus includes expanding their integrated offerings, combining their technology leadership with comprehensive CRO services, particularly in areas like cell and gene therapy and precision medicine.

  • Competitive Positioning and Strategic Focus: Thermo Fisher’s competitive edge comes from its unparalleled portfolio of scientific tools and technologies, now complemented by full-service CRO capabilities via PPD. Their strategic focus is on being the preferred partner for enabling scientific research and clinical development by providing innovative products and comprehensive services.

  • Key Customers or Industries Served: Pharmaceutical and biotechnology companies, academic and research institutions, clinical diagnostic labs, and government agencies.

6. WuXi AppTec

  • Company Name and Headquarters: WuXi AppTec Inc., Shanghai, China (global operations)

  • Product Offerings related to Biomarker Discovery Outsourcing Services: WuXi AppTec offers a wide array of integrated R&D and manufacturing services, including extensive biomarker discovery and validation capabilities. This encompasses genomics (e.g., NGS, qPCR), proteomics (e.g., mass spectrometry, immunoassay), cell-based assays, and bioinformatics support, often integrated into their broader drug discovery and development platforms.

  • Market Share and Estimated Revenue from Biomarker Discovery Outsourcing Services Segment: WuXi AppTec is a leading global contract research, development, and manufacturing organization (CRDMO). While specific biomarker revenue isn’t broken out, their laboratory services segment is a major contributor, with biomarker services being a crucial component of their early drug discovery and preclinical offerings.

  • Recent Developments, Partnerships, or Innovations: WuXi AppTec consistently invests in new technologies and expands its capacity, particularly in areas like cell and gene therapy, and oligonucleotide synthesis. They are known for their integrated platforms that streamline drug development processes.

  • Competitive Positioning and Strategic Focus: WuXi AppTec’s strength lies in its integrated “end-to-end” CRDMO model, offering a comprehensive suite of services from discovery to commercial manufacturing. Their strategic focus is on providing high-quality, efficient, and flexible solutions to global biopharmaceutical clients, accelerating their R&D pipelines.

  • Key Customers or Industries Served: Global pharmaceutical and biotechnology companies.

7. Syneos Health

  • Company Name and Headquarters: Syneos Health, Inc., Morrisville, North Carolina, USA

  • Product Offerings related to Biomarker Discovery Outsourcing Services: Syneos Health, as an integrated biopharmaceutical solutions organization, provides strategic consulting, clinical development (CRO), and commercialization services. Their biomarker discovery outsourcing services are typically embedded within their clinical trial offerings, including biomarker strategy, assay development and validation, sample analysis (through partner labs or in-house capabilities), and data interpretation for patient stratification and drug response.

  • Market Share and Estimated Revenue from Biomarker Discovery Outsourcing Services Segment: Syneos Health is a leading global CRO. While biomarker services are not a standalone revenue segment, they are integral to their clinical development business, particularly in therapeutic areas like oncology and immunology where biomarkers are critical.

  • Recent Developments, Partnerships, or Innovations: Syneos Health has been focusing on integrating clinical and commercial insights to optimize drug development, often involving sophisticated biomarker strategies. They also invest in digital technologies and data analytics to enhance trial efficiency.

  • Competitive Positioning and Strategic Focus: Syneos Health’s unique position is its integration of clinical development and commercialization services, aiming to accelerate product uptake. Their strategic focus is on providing comprehensive solutions that bridge the gap between clinical success and market access, with biomarkers informing both aspects.

  • Key Customers or Industries Served: Pharmaceutical, biotechnology, and medical device companies.

8. Q² Solutions (IQVIA & Quest Diagnostics JV)

  • Company Name and Headquarters: Q² Solutions (Joint Venture between IQVIA and Quest Diagnostics), Durham, North Carolina, USA

  • Product Offerings related to Biomarker Discovery Outsourcing Services: Q² Solutions is a leading global clinical trial laboratory services organization. They offer a vast array of biomarker discovery and validation services, including genomics, proteomics, flow cytometry, immunology, and histology. They specialize in developing and deploying validated assays for clinical trials, managing sample logistics, and providing comprehensive data analysis.

  • Market Share and Estimated Revenue from Biomarker Discovery Outsourcing Services Segment: Q² Solutions holds a significant share in the central laboratory market, which is crucial for biomarker services in clinical trials. Their revenue is substantial, driven by the demand for high-quality, globally harmonized laboratory testing.

  • Recent Developments, Partnerships, or Innovations: Q² Solutions continuously invests in expanding its global lab footprint, enhancing its assay development capabilities, and integrating advanced technologies (e.g., next-generation sequencing, single-cell analysis) to support complex biomarker programs.

  • Competitive Positioning and Strategic Focus: Q² Solutions leverages the strengths of its parent companies – IQVIA’s clinical trial expertise and Quest Diagnostics’ diagnostic capabilities and scale. Their strategic focus is on being the premier central laboratory solution for clinical trials, providing harmonized, high-quality, and globally consistent biomarker testing and data.

  • Key Customers or Industries Served: Pharmaceutical and biotechnology companies.

9. Bio-Rad Laboratories

  • Company Name and Headquarters: Bio-Rad Laboratories, Inc., Hercules, California, USA

  • Product Offerings related to Biomarker Discovery Outsourcing Services: Bio-Rad is primarily a manufacturer of life science research and clinical diagnostic products. While not a full-service CRO, they offer specialized outsourced services, particularly in protein-based biomarker discovery using their proprietary platforms like droplet digital PCR (ddPCR) for nucleic acid biomarkers and various immunoassay platforms. They also provide custom antibody services and cell-based assay development.

  • Market Share and Estimated Revenue from Biomarker Discovery Outsourcing Services Segment: Bio-Rad holds a strong market position in laboratory reagents and instruments. Revenue from direct biomarker discovery outsourcing services is a smaller, specialized component, but their tools are widely used by other CROs and pharmaceutical companies for biomarker work.

  • Recent Developments, Partnerships, or Innovations: Bio-Rad continuously innovates in areas like single-cell analysis, gene editing tools, and advanced immunoassay development. They focus on expanding the applications of their ddPCR technology for highly sensitive biomarker detection.

  • Competitive Positioning and Strategic Focus: Bio-Rad’s strength lies in its innovative technologies and high-quality reagents and instruments for life science research and diagnostics. Their strategic focus is on providing enabling tools and specialized services that advance scientific discovery, including critical tools for biomarker research.

  • Key Customers or Industries Served: Academic and research institutions, pharmaceutical and biotechnology companies, clinical diagnostic laboratories.

10. PPD Inc. (now part of Thermo Fisher Scientific)

  • Company Name and Headquarters: PPD Inc. (acquired by Thermo Fisher Scientific in 2021), Wilmington, North Carolina, USA

  • Product Offerings related to Biomarker Discovery Outsourcing Services: PPD, as a leading global CRO, offers end-to-end clinical research services, including comprehensive biomarker strategy development, assay design and validation, central laboratory services (genomics, proteomics, flow cytometry, immunology), and advanced bioinformatics and data analytics for biomarker identification and validation in clinical trials.

  • Market Share and Estimated Revenue from Biomarker Discovery Outsourcing Services Segment: Prior to acquisition, PPD was one of the top global CROs. Now as part of Thermo Fisher Scientific, its biomarker services contribute significantly to Thermo Fisher’s CRO segment revenue.

  • Recent Developments, Partnerships, or Innovations: As part of Thermo Fisher, PPD benefits from integration with Thermo Fisher’s vast technology and product portfolio. The focus is on leveraging this synergy to provide more integrated and innovative solutions for clients, particularly in precision medicine.

  • Competitive Positioning and Strategic Focus: PPD’s strength lies in its global reach, operational excellence, and deep scientific and therapeutic expertise across all phases of clinical development. Its strategic focus, now under Thermo Fisher, is to provide comprehensive, integrated solutions that combine leading CRO services with unparalleled scientific tools and technologies.

  • Key Customers or Industries Served: Global pharmaceutical and biotechnology companies.

11. SGS SA

  • Company Name and Headquarters: SGS SA, Geneva, Switzerland

  • Product Offerings related to Biomarker Discovery Outsourcing Services: SGS is a global leader in inspection, verification, testing, and certification services. Within its Health & Nutrition segment, it offers extensive contract research services, including a broad range of bioanalytical services for biomarker discovery and validation. This includes genomics, proteomics, small molecule analysis, and specialized assays for preclinical and clinical studies.

  • Market Share and Estimated Revenue from Biomarker Discovery Outsourcing Services Segment: SGS is a significant player in the broader testing and inspection market. Their Life Sciences services, particularly bioanalysis and clinical research, contribute a notable portion of revenue, with biomarker services being a key offering.

  • Recent Developments, Partnerships, or Innovations: SGS continuously invests in expanding its laboratory capabilities and expertise, particularly in specialized areas like large molecule bioanalysis and biosafety testing. They focus on global standardization and quality.

  • Competitive Positioning and Strategic Focus: SGS’s strength is its global network and reputation for quality, integrity, and regulatory compliance across diverse industries. Their strategic focus in life sciences is on providing high-quality, reliable, and globally harmonized testing and clinical research services, supporting drug development from discovery to market.

  • Key Customers or Industries Served: Pharmaceutical and biotechnology companies, medical device manufacturers, and various other industries requiring analytical testing.

12. Evotec SE

  • Company Name and Headquarters: Evotec SE, Hamburg, Germany

  • Product Offerings related to Biomarker Discovery Outsourcing Services: Evotec is a leading drug discovery and development company with a strong focus on innovative solutions. They offer comprehensive biomarker discovery and validation services integrated into their drug discovery alliances. This includes genomics, proteomics, metabolomics, high-throughput screening, target identification, and phenotypic screening, with a strong emphasis on data-driven approaches and artificial intelligence (AI) for biomarker identification.

  • Market Share and Estimated Revenue from Biomarker Discovery Outsourcing Services Segment: Evotec is a prominent player in the drug discovery services market. While specific biomarker revenue is not segmented, it is a core component of their integrated discovery and development solutions, which generate substantial revenue.

  • Recent Developments, Partnerships, or Innovations: Evotec is highly innovative, with numerous strategic partnerships with pharmaceutical companies and academic institutions. They actively invest in cutting-edge platforms, including induced pluripotent stem cells (iPSC) for disease modeling and AI/machine learning for data analysis and biomarker identification.

  • Competitive Positioning and Strategic Focus: Evotec’s strength lies in its unique business model of “externalizing R&D” for clients, offering end-to-end integrated drug discovery solutions. Their strategic focus is on leveraging their proprietary platforms, deep scientific expertise, and data-driven approaches to accelerate the discovery and development of novel therapeutics, with biomarkers being central to their approach.

  • Key Customers or Industries Served: Pharmaceutical companies, biotechnology firms, and academic institutions.

13. Creative Biolabs

  • Company Name and Headquarters: Creative Biolabs, Shirley, New York, USA

  • Product Offerings related to Biomarker Discovery Outsourcing Services: Creative Biolabs is a contract research organization specializing in a wide range of customized biotechnology and pharmaceutical services. For biomarker discovery, they offer extensive services in antibody development, immunoassay development (ELISA, Western Blot), protein expression and purification, cell-based assays, and custom peptide synthesis, all critical for identifying and validating protein and peptide biomarkers.

  • Market Share and Estimated Revenue from Biomarker Discovery Outsourcing Services Segment: Creative Biolabs is a niche player with a strong focus on specialized antibody and immunoassay development services, which are fundamental to protein biomarker work. Their revenue from biomarker services is generally smaller compared to full-service CROs but significant within their specialized domain.

  • Recent Developments, Partnerships, or Innovations: They continuously expand their service portfolio in emerging areas like CAR-T cell therapy development, bispecific antibodies, and phage display technology, all of which often involve novel biomarker identification.

  • Competitive Positioning and Strategic Focus: Creative Biolabs’ strength is its highly customizable and specialized services, particularly in antibody and immunoassay development. Their strategic focus is on providing flexible, high-quality solutions to research and development challenges, enabling clients to accelerate their programs, especially in biologic drug discovery.

  • Key Customers or Industries Served: Academic research institutions, biotechnology companies, and pharmaceutical companies.

14. GenScript Biotech Corporation

  • Company Name and Headquarters: GenScript Biotech Corporation, Nanjing, China (global operations)

  • Product Offerings related to Biomarker Discovery Outsourcing Services: GenScript is a leading life science research tools and services provider. Their biomarker discovery outsourcing services primarily focus on gene synthesis, peptide synthesis, protein expression and purification, antibody development, and cell line development. These are foundational services for identifying and validating genetic, protein, and cellular biomarkers.

  • Market Share and Estimated Revenue from Biomarker Discovery Outsourcing Services Segment: GenScript holds a dominant position in gene and peptide synthesis. Revenue from direct “biomarker discovery outsourcing” is embedded within their broader contract research and manufacturing services for gene, peptide, and protein synthesis.

  • Recent Developments, Partnerships, or Innovations: GenScript continually invests in improving its synthesis capabilities and expanding its offerings in areas like cell and gene therapy (through its ProBio division) and industrial enzymes. They are known for rapid turnaround times and high-quality synthetic biology tools.

  • Competitive Positioning and Strategic Focus: GenScript’s strength lies in its unparalleled capabilities in gene, peptide, and protein synthesis, offering high-quality and cost-effective solutions. Their strategic focus is on being the “biology CRO” that provides essential building blocks and services for fundamental research and biopharmaceutical development, including tools for biomarker identification.

  • Key Customers or Industries Served: Academic and research institutions, biotechnology companies, and pharmaceutical companies.

15. DiscoverX (part of Eurofins Discovery)

  • Company Name and Headquarters: DiscoverX (part of Eurofins Discovery), Fremont, California, USA (Eurofins Discovery is headquartered in St. Charles, Missouri, USA)

  • Product Offerings related to Biomarker Discovery Outsourcing Services: DiscoverX, now integrated into Eurofins Discovery, specializes in cell-based assays and services for drug discovery, including target validation, compound profiling, and the identification of functional biomarkers. Their offerings leverage proprietary technologies like enzyme fragment complementation (EFC) for sensitive detection of protein-protein interactions and signaling pathways, which are key for functional biomarker identification.

  • Market Share and Estimated Revenue from Biomarker Discovery Outsourcing Services Segment: DiscoverX (as part of Eurofins Discovery) holds a strong position in the functional cell-based assay market. Revenue is integrated into Eurofins Discovery’s broader portfolio, which focuses on early-stage drug discovery services.

  • Recent Developments, Partnerships, or Innovations: As part of Eurofins Discovery, DiscoverX’s technologies are integrated into a broader service portfolio, enhancing Eurofins’ capabilities in high-throughput screening and functional genomics for biomarker discovery.

  • Competitive Positioning and Strategic Focus: DiscoverX, within Eurofins Discovery, offers specialized, high-quality functional assay technologies. Their strategic focus is on providing innovative cell-based solutions that accelerate early-stage drug discovery by offering reliable and sensitive tools for target validation and functional biomarker identification.

  • Key Customers or Industries Served: Pharmaceutical companies, biotechnology companies, and academic research institutions.

16. Proteome Sciences plc

  • Company Name and Headquarters: Proteome Sciences plc, London, UK

  • Product Offerings related to Biomarker Discovery Outsourcing Services: Proteome Sciences is a specialist in proteomic biomarker discovery and validation. They offer comprehensive services using their proprietary TMT® (Tandem Mass Tag) mass spectrometry platform for quantitative protein analysis, as well as isobaric mass tagging and immunoassay development. They focus on identifying novel protein biomarkers for disease diagnosis, prognosis, and drug response across various therapeutic areas.

  • Market Share and Estimated Revenue from Biomarker Discovery Outsourcing Services Segment: Proteome Sciences is a niche but highly specialized player in the proteomics market. Their revenue is driven by their proprietary TMT® reagents and their contract research services in proteomic biomarker discovery.

  • Recent Developments, Partnerships, or Innovations: They continually enhance their TMT® technology and expand its applications. They also focus on developing diagnostic assays based on their discovered biomarkers and entering strategic partnerships for clinical validation.

  • Competitive Positioning and Strategic Focus: Proteome Sciences’ strength lies in its deep expertise and proprietary technology in quantitative proteomics. Their strategic focus is on discovering and validating high-value protein biomarkers and translating them into diagnostic and prognostic tools, particularly in areas like neurodegenerative diseases and oncology.

  • Key Customers or Industries Served: Pharmaceutical companies, biotechnology firms, academic research institutions, and diagnostic companies.

17. Medpace Holdings, Inc. 

  • Company Name and Headquarters: Medpace Holdings, Inc., Cincinnati, Ohio, USA

  • Product Offerings related to Biomarker Discovery Outsourcing Services: Medpace is a scientifically driven, global full-service CRO. They offer comprehensive biomarker discovery and validation services integrated into their clinical trial offerings. This includes a robust central laboratory with capabilities in genomics, flow cytometry, immunoassay, and specialized molecular diagnostics. They focus on biomarker strategies for patient selection, pharmacodynamics, and safety assessment in complex therapeutic areas.

  • Market Share and Estimated Revenue from Biomarker Discovery Outsourcing Services Segment: Medpace is a leading mid-sized to large global CRO, known for its deep therapeutic expertise. Biomarker services are a crucial component of their central lab and clinical research offerings, particularly in oncology, cardiology, and CNS.

  • Recent Developments, Partnerships, or Innovations: Medpace consistently invests in expanding its in-house central laboratory capabilities and therapeutic expertise. They focus on optimizing clinical trial design and execution, with biomarkers playing a central role in their integrated approach.

  • Competitive Positioning and Strategic Focus: Medpace’s strength is its scientifically driven approach and therapeutic area expertise, particularly in complex diseases. Their strategic focus is on providing high-quality, full-service clinical development solutions, leveraging their in-house central laboratory and scientific staff to accelerate drug development.

  • Key Customers or Industries Served: Pharmaceutical and biotechnology companies, particularly those developing novel and complex therapies.

18. Precision for Medicine

  • Company Name and Headquarters: Precision for Medicine (part of Precision Value & Health), Bethesda, Maryland, USA

  • Product Offerings related to Biomarker Discovery Outsourcing Services: Precision for Medicine is a specialized CRO dedicated to supporting the development and commercialization of precision medicines. They offer end-to-end biomarker services, including biomarker strategy, assay development and validation (genomics, proteomics, flow cytometry, IHC), central laboratory testing, companion diagnostic development, and bioinformatics.

  • Market Share and Estimated Revenue from Biomarker Discovery Outsourcing Services Segment: Precision for Medicine is a significant and highly specialized player in the precision medicine CRO space. Their entire business is centered around biomarkers and personalized medicine, making this segment a core revenue driver.

  • Recent Developments, Partnerships, or Innovations: Precision for Medicine continuously expands its laboratory capabilities and expertise in cutting-edge areas like cell and gene therapy, spatial biology, and advanced molecular diagnostics. They often form strategic partnerships to bring novel precision therapies to market.

  • Competitive Positioning and Strategic Focus: Precision for Medicine’s unique strength is its exclusive focus and deep expertise in precision medicine and companion diagnostics. Their strategic focus is on providing specialized, integrated solutions that enable the successful development and commercialization of targeted therapies, with biomarkers at the heart of their strategy.

  • Key Customers or Industries Served: Pharmaceutical and biotechnology companies developing precision medicines, often in oncology, rare diseases, and immunology.

19. Sino Biological Inc.

  • Company Name and Headquarters: Sino Biological Inc., Beijing, China (global operations)

  • Product Offerings related to Biomarker Discovery Outsourcing Services: Sino Biological is a leading research reagent and service provider. Their biomarker discovery outsourcing services primarily focus on recombinant protein production, antibody development (monoclonal and polyclonal), gene synthesis, and cell line development. These services are essential for generating high-quality reagents and tools required for the identification, validation, and detection of protein and nucleic acid biomarkers.

  • Market Share and Estimated Revenue from Biomarker Discovery Outsourcing Services Segment: Sino Biological is a strong player in the recombinant protein and antibody market. Revenue from direct “biomarker discovery outsourcing” is embedded within their broader contract manufacturing and research services for reagents.

  • Recent Developments, Partnerships, or Innovations: Sino Biological consistently expands its product catalog, particularly in highly relevant research areas (e.g., infectious diseases, immunology, oncology). They are known for high-quality protein and antibody reagents with rapid delivery.

  • Competitive Positioning and Strategic Focus: Sino Biological’s strength lies in its high-quality, comprehensive portfolio of recombinant proteins and antibodies. Their strategic focus is on being the premier supplier of research reagents and custom services that empower scientific discovery and drug development, including the fundamental tools for biomarker research.

  • Key Customers or Industries Served: Academic and research institutions, biotechnology companies, and pharmaceutical companies.

20. Biomarker Technologies, Inc.

  • Company Name and Headquarters: Biomarker Technologies, Inc., Beijing, China (global operations)

  • Product Offerings related to Biomarker Discovery Outsourcing Services: Biomarker Technologies specializes in multi-omics services (genomics, transcriptomics, proteomics, metabolomics, epigenomics, bioinformatics) for comprehensive biomarker discovery. They offer services like next-generation sequencing, mass spectrometry, gene expression profiling, and advanced data analysis for disease research, drug development, and agricultural applications.

  • Market Share and Estimated Revenue from Biomarker Discovery Outsourcing Services Segment: Biomarker Technologies is a specialized multi-omics service provider, particularly active in Asia. Their revenue is directly derived from providing comprehensive biomarker discovery and analysis services.

  • Recent Developments, Partnerships, or Innovations: They continuously invest in cutting-edge multi-omics technologies and advanced bioinformatics pipelines to handle large and complex datasets. Their focus includes expanding applications in precision agriculture and animal health in addition to human health.

  • Competitive Positioning and Strategic Focus: Biomarker Technologies’ strength lies in its integrated multi-omics platforms and bioinformatics expertise for comprehensive biomarker identification. Their strategic focus is on providing high-quality, integrated omics solutions to accelerate research and development across various life science fields.

  • Key Customers or Industries Served: Academic and research institutions, pharmaceutical and biotechnology companies, and agricultural research organizations.

Contact Us

Related Posts

Scroll to Top